Jonathan Rubin, MD, MBA, has been the Chief Medical Officer and Senior Vice President of Research & Development at Supernus Pharmaceuticals, Inc. since January 1, 2021. Before joining the Company on February 10, 2020, as Senior Vice-President, Clinical Research and Medical Affairs, Dr. Rubin was Chief Medical Officer of Atentiv, Inc. from 2018 to 2020, where he was responsible for clinical strategy and the design of clinical trials. From 2017 to 2018, Dr. Rubin was a clinical consultant to Chondrial Therapeutics, Inc. responsible for developing clinical strategy and trials. From 2013 to 2017, Dr. Rubin was Chief Medical Officer of Alcobra, Inc., where he was responsible for oversight of the company’s clinical development, medical affairs, biometrics and pharmacovigilance departments, and he participated in the completion of two Phase III studies in ADHD and assisted with orphan drug and fast track designations for product candidates. From 2007 to 2013, Dr. Rubin was Medical Director of Clinical Development and Medical Affairs for Shire Pharmaceuticals, where he supported the company’s ADHD portfolio and assisted with the design, execution and interpretation of Phase II, Phase IIIB and Phase IV studies. Prior to entering the biopharmaceutical industry, Dr. Rubin was in private practice as a Developmental-Behavioral and General Pediatrician for 16 years. Dr. Rubin was a pediatric resident at Albert Einstein/Montefiore Hospital in the Bronx, New York and a fellow in ambulatory pediatrics at Boston’s Children Hospital. Dr. Rubin received his M.D. from the University of Connecticut School of Medicine, his Master of Business Administration from the Columbia School of Business and his Bachelor of Science in molecular biophysics and biochemistry from Yale University.
What is Jonathan Rubin's net worth?
The estimated net worth of Jonathan Rubin is at least $352.17 thousand as of February 21st, 2025. Dr. Rubin owns 7,853 shares of Supernus Pharmaceuticals stock worth more than $352,168 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Rubin may own. Additionally, Dr. Rubin receives a salary of $594,650.00 as Senior Vice President, Chief Medical Officer, Research & Development at Supernus Pharmaceuticals. Learn More about Jonathan Rubin's net worth.
How old is Jonathan Rubin?
Dr. Rubin is currently 63 years old. There are 5 older executives and no younger executives at Supernus Pharmaceuticals. The oldest executive at Supernus Pharmaceuticals is Ms. Tami T. Martin Esq., R.N., Senior Vice President of Regulatory Affairs, who is 69 years old. Learn More on Jonathan Rubin's age.
What is Jonathan Rubin's salary?
As the Senior Vice President, Chief Medical Officer, Research & Development of Supernus Pharmaceuticals, Inc., Dr. Rubin earns $594,650.00 per year. There are 2 executives that earn more than Dr. Rubin. The highest earning executive at Supernus Pharmaceuticals is Mr. Jack A. Khattar, Founder, President, CEO, Secretary & Director, who commands a salary of $1,630,000.00 per year. Learn More on Jonathan Rubin's salary.
How do I contact Jonathan Rubin?
Has Jonathan Rubin been buying or selling shares of Supernus Pharmaceuticals?
Jonathan Rubin has not been actively trading shares of Supernus Pharmaceuticals during the last quarter. Most recently, Jonathan Rubin sold 927 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a transaction totalling $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. Learn More on Jonathan Rubin's trading history.
Who are Supernus Pharmaceuticals' active insiders?
Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Timothy Dec (CFO), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development), and Bethany Sensenig (Director). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?
In the last twelve months, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 373,845 shares worth more than $16,830,854.81. The most recent insider tranaction occured on October, 9th when CEO Jack A Khattar sold 59,900 shares worth more than $3,029,143.00. Insiders at Supernus Pharmaceuticals own 8.8% of the company.
Learn More about insider trades at Supernus Pharmaceuticals. Information on this page was last updated on 10/9/2025.
